Literature DB >> 20607689

High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis.

Rohit Kohli1, Michelle Kirby, Stavra A Xanthakos, Samir Softic, Ariel E Feldstein, Vijay Saxena, Peter H Tang, Lili Miles, Michael V Miles, William F Balistreri, Stephen C Woods, Randy J Seeley.   

Abstract

UNLABELLED: Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans. We hypothesized that mice exposed to a similar diet would develop NASH with fibrosis associated with increased hepatic oxidative stress that would be further reflected by increased plasma levels of the respiratory chain component, oxidized coenzyme Q9 ((ox)CoQ9). Adult male C57Bl/6 mice were randomly assigned to chow, high-fat (HF), or high-fat high-carbohydrate (HFHC) diets for 16 weeks. The chow and HF mice had free access to pure water, whereas the HFHC group received water with 55% fructose and 45% sucrose (wt/vol). The HFHC and HF groups had increased body weight, body fat mass, fasting glucose, and were insulin-resistant compared with chow mice. HF and HFHC consumed similar calories. Hepatic triglyceride content, plasma alanine aminotransferase, and liver weight were significantly increased in HF and HFHC mice compared with chow mice. Plasma cholesterol (P < 0.001), histological hepatic fibrosis, liver hydroxyproline content (P = 0.006), collagen 1 messenger RNA (P = 0.003), CD11b-F4/80+Gr1+ monocytes (P < 0.0001), transforming growth factor beta1 mRNA (P = 0.04), and alpha-smooth muscle actin messenger RNA (P = 0.001) levels were significantly increased in HFHC mice. Hepatic oxidative stress, as indicated by liver superoxide expression (P = 0.002), 4-hydroxynonenal, and plasma (ox)CoQ9 (P < 0.001) levels, was highest in HFHC mice.
CONCLUSION: These findings demonstrate that nongenetically modified mice maintained on an HFHC diet in addition to developing obesity have increased hepatic ROS and a NASH-like phenotype with significant fibrosis. Plasma (ox)CoQ9 correlated with fibrosis progression. The mechanism of fibrosis may involve fructose inducing increased ROS associated with CD11b+F4/80+Gr1+ hepatic macrophage aggregation, resulting in transforming growth factor beta1-signaled collagen deposition and histologically visible hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607689      PMCID: PMC2932817          DOI: 10.1002/hep.23797

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  47 in total

Review 1.  From fat to inflammation.

Authors:  Christopher Paul Day
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

Review 2.  Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism.

Authors:  Peter J Havel
Journal:  Nutr Rev       Date:  2005-05       Impact factor: 7.110

3.  Carnitine treatment inhibits increases in cerebral carnitine esters and glutamate detected by mass spectrometry after hypoxia-ischemia in newborn rats.

Authors:  Mark S Wainwright; Rohit Kohli; Peter F Whitington; Donald H Chace
Journal:  Stroke       Date:  2005-12-29       Impact factor: 7.914

4.  Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis.

Authors:  Jacob George; Natasha Pera; Nghi Phung; Isabelle Leclercq; Jing Yun Hou; Geoffrey Farrell
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

5.  Antioxidant role of cellular reduced coenzyme Q homologs and alpha-tocopherol in free radical-induced injury of hepatocytes isolated from rats fed diets with different vitamin E contents.

Authors:  T Matsura; K Yamada; T Kawasaki
Journal:  Biochim Biophys Acta       Date:  1992-08-19

6.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

7.  Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent.

Authors:  Laura H Tetri; Metin Basaranoglu; Elizabeth M Brunt; Lisa M Yerian; Brent A Neuschwander-Tetri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

8.  Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.

Authors:  Atul Sahai; Padmini Malladi; Hector Melin-Aldana; Richard M Green; Peter F Whitington
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-03-25       Impact factor: 4.052

9.  Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway.

Authors:  Rohit Kohli; Xiaomin Pan; Padmini Malladi; Mark S Wainwright; Peter F Whitington
Journal:  J Biol Chem       Date:  2007-05-31       Impact factor: 5.157

10.  Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice.

Authors:  Jude A Oben; Tania Roskams; Shiqi Yang; Huizhi Lin; Nicoletta Sinelli; Zhiping Li; Michael Torbenson; Steven A Thomas; Anna Mae Diehl
Journal:  Biochem Biophys Res Commun       Date:  2003-08-22       Impact factor: 3.575

View more
  141 in total

1.  Nutrigenomics of hepatic steatosis in a feline model: effect of monosodium glutamate, fructose, and Trans-fat feeding.

Authors:  Kate S Collison; Marya Z Zaidi; Soad M Saleh; Nadine J Makhoul; Angela Inglis; Joey Burrows; Joseph A Araujo; Futwan A Al-Mohanna
Journal:  Genes Nutr       Date:  2011-12-06       Impact factor: 5.523

Review 2.  Fatty liver disease in children--what should one do?

Authors:  Kristin S Bramlage; Vivek Bansal; Stavra A Xanthakos; Rohit Kohli
Journal:  Indian J Pediatr       Date:  2012-06-22       Impact factor: 1.967

Review 3.  Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Authors:  Samar H Ibrahim; Petra Hirsova; Harmeet Malhi; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2015-12-01       Impact factor: 3.199

Review 4.  Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.

Authors:  Johanna K DiStefano
Journal:  Cell Mol Life Sci       Date:  2020-06       Impact factor: 9.261

5.  Mouse Models of Liver Fibrosis.

Authors:  Aashreya Ravichandra; Robert F Schwabe
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Hepatic inflammation and fibrosis: functional links and key pathways.

Authors:  Ekihiro Seki; Robert F Schwabe
Journal:  Hepatology       Date:  2015-01-28       Impact factor: 17.425

7.  High fat diet feeding results in gender specific steatohepatitis and inflammasome activation.

Authors:  Michal Ganz; Timea Csak; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

8.  Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.

Authors:  Melissa A Linden; Ryan D Sheldon; Grace M Meers; Laura C Ortinau; E Matthew Morris; Frank W Booth; Jill A Kanaley; Victoria J Vieira-Potter; James R Sowers; Jamal A Ibdah; John P Thyfault; M Harold Laughlin; R Scott Rector
Journal:  J Physiol       Date:  2016-05-27       Impact factor: 5.182

9.  Dissociation of hepatic insulin resistance from susceptibility of nonalcoholic fatty liver disease induced by a high-fat and high-carbohydrate diet in mice.

Authors:  Akihiro Asai; Pauline M Chou; Heng-Fu Bu; Xiao Wang; M Sambasiva Rao; Anthony Jiang; Christine J DiDonato; Xiao-Di Tan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-01-16       Impact factor: 4.052

10.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.